Drug Abuse Aspects of HIV/AIDS (R03) | Apply Online

FAQs: Drug Abuse Aspects of HIV/AIDS (R03) (PA-07-308)

What is the Drug Abuse Aspects of HIV/AIDS (R03) opportunity (PA-07-308)?

PA-07-308 is a National Institutes of Health (NIH) grant announcement issued by the National Institute on Drug Abuse (NIDA). It supports small, targeted research projects focused on the intersection of substance use and HIV/AIDS, especially projects that can move quickly on emerging prevention and drug abuse research needs.

What grant mechanism does this opportunity use?

This opportunity uses the NIH R03 mechanism, which is intended for smaller-scope projects that can generate early findings, test new ideas, refine methods, pilot interventions, or produce preliminary data that can support larger future studies.

What is the central aim of the program?

The central aim is to fund focused studies that help explain, predict, and prevent HIV risk where drug use plays a role, and to stimulate practical, innovative research that responds to real-world shifts in HIV transmission and impact.

What research topics does NIDA emphasize in this announcement?

The announcement emphasizes drug abuse-related HIV/AIDS research tied to prevention and changing patterns of the epidemic. It highlights the importance of understanding HIV risk in contexts where substance use affects judgment, sexual risk-taking, or injection practices.

Why does the opportunity focus on changing patterns in the U.S. HIV/AIDS epidemic?

The announcement notes shifts in who is most affected and how transmission occurs, including the growing overrepresentation of racial and ethnic minorities and women among new AIDS cases and the increasing significance of heterosexual sex as a transmission route. The intent is to encourage prevention research that better matches these evolving patterns.

Does the program prioritize prevention research?

Yes. A major theme is the need for novel or improved preventive interventions and research that identifies behavioral, social, or structural factors contributing to HIV vulnerability in the presence of substance use.

What kinds of projects are appropriate for an R03 under this opportunity?

Projects are expected to be small and targeted, such as pilot studies, early-stage testing of new concepts, development or refinement of research methods, adaptation of interventions for underserved groups, or generating data to justify larger future studies.

Does the announcement support adapting existing interventions for specific populations?

Yes. The announcement explicitly discusses designing new approaches and adapting existing interventions to better serve underserved groups and to address evolving HIV transmission patterns in contexts involving drug use.

Is international research allowed or encouraged?

Yes. The opportunity explicitly supports international work, including studying HIV and drug abuse dynamics in other countries and translating or adapting interventions shown effective in the U.S. for different international settings and communities.

What does "translation and adaptation" of interventions mean in the context of this announcement?

It refers to studying what needs to change for an intervention to work in a new cultural, economic, or health-system context, and how adapting an intervention affects its implementation and potential impact in different communities or countries.

Does the announcement also value lessons learned from comparing different cultures or settings?

Yes. It encourages learning in both directions, including using differences across conditions and cultures to better understand why HIV-related risks, illness patterns, and outcomes vary across populations.

What kinds of differences across populations and settings are of interest?

The announcement describes interest in differences in HIV risk linked to drug abuse as well as differences in morbidity and mortality across diverse groups and settings.

Is this a discretionary grant program, and what CFDA number is associated with it?

Yes. It is described as a discretionary grant program under NIH and is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs).

Is cost sharing or matching required?

No. The listing specifies that cost sharing or matching is not required.

When was this opportunity posted?

The posting date is January 17, 2007.

Is there a single deadline for applications?

No. The opportunity used multiple receipt dates rather than a single deadline, with the full schedule and submission details provided in the full announcement.

What does the archive date mean for this opportunity?

The listing shows an archive date of February 2, 2010. The summary describes what the program was designed to fund and the types of applicants it was open to, but the official requirements and timing were provided in the full announcement.

Who is eligible to apply?

Eligibility is broad and includes many organization types capable of conducting research. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status (including faith-based and community-based organizations); small businesses; other for-profit organizations (with distinctions noted in the full announcement); Native American tribal governments (federally recognized) and tribal organizations (non-federally recognized); and public housing authorities/Indian housing authorities.

Are foreign institutions eligible to apply?

Yes. The announcement states that foreign institutions are eligible to apply, consistent with the program's interest in domestic and international research capacity.

Can federal agencies apply?

Yes. The announcement states that eligible federal agencies may apply.

Where can applicants find the official full announcement?

The full announcement was available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-07-308.html.

Where were technical access issues directed?

Technical access issues were routed to the NIH Office of Extramural Research webmaster contact listed in the notice.